Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-24First oral medicine targeting interleukin-23 receptor recommended for plaque psoriasis
The EMA recommends the first oral medicine that targets the interleukin-23 receptor for plaque psoriasis, showing potential to clear skin le…
-
FDA approval · 2026-04-15FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab submitted by Janssen Biotech, Inc. The action pertains to a supplemental submission …
-
FDA approval · 2026-03-06FDA Approved: SKYRIZI — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for SKYRIZI (risankizumab-rzaa) from AbbVie Inc. The action updates or expands the drug's regulatory…
-
FDA approval · 2026-01-07FDA Approved: YESINTEK — Supplemental Application (Biocon Biologics Inc.)
The FDA approved a supplemental application for YESINTEK (ustekinumab) from Biocon Biologics Inc. The action relates to the ustekinumab bios…
-
FDA approval · 2025-12-23FDA Approved: OTEZLA — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for OTEZLA (apremilast) from Amgen, Inc. The approval updates the labeling for the product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-12-16EMA Authorised: Erelzi (etanercept) — Sandoz GmbH
The EMA authorised Erelzi (etanercept) by Sandoz GmbH as a biosimilar to treat several inflammatory conditions including rheumatoid arthriti…
-
FDA approval · 2025-12-12FDA Approved: ILUMYA — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for ILUMYA (tildrakizumab-asmn) submitted by Sun Pharmaceutical Industries, Inc. The action updates …
-
FDA approval · 2025-12-01FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for SELARSDI (USTEKINUMAB-AEKN), a biosimilar to ustekinumab.
-
FDA approval · 2025-11-20FDA Approved: IMULDOSA — Supplemental Application (Accord BioPharma Inc.)
FDA approved a supplemental application for IMULDOSA (USTEKINUMAB-SRLF) from Accord BioPharma Inc. The action updates the regulatory status …
-
FDA approval · 2025-11-19FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for SELARSDI (ustekinumab-aeKn) from Teva Pharmaceuticals USA, Inc. The product is a ustekinumab bio…
-
FDA approval · 2025-11-18FDA Approved: USTEKINUMAB-TTWE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for USTEKINUMAB-TTWE from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2025-11-03FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for Ustekinumab (Stelara) from Janssen Biotech, Inc., related to regulatory changes to its label…
-
FDA approval · 2025-10-28FDA Approved: RENFLEXIS — Supplemental Application (Organon LLC)
FDA approved a supplemental application for RENFLEXIS (infliximab) submitted by Organon LLC. The approval updates the product labeling to re…
-
FDA approval · 2025-10-17FDA Approved: HADLIMA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for HADLIMA (adalimumab-bwwd) from Organon LLC, supporting expanded indications for this adalimumab …
-
FDA approval · 2025-10-16FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ (tofacitinib) filed by Pfizer Laboratories Div Pfizer Inc, resulting in changes to t…
-
FDA approval · 2025-10-16FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
FDA approved a supplemental application for Amjevita (adalimumab-atto) submitted by Nuvaila Limited.
-
FDA approval · 2025-10-04FDA Approved: ZORYVE — Supplemental Application (Arcutis Biotherapeutics, Inc.)
The FDA approved a supplemental application for ZORYVE (roflumilast) from Arcutis Biotherapeutics, resulting in updated labeling for the pro…
-
FDA approval · 2025-09-17FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
The FDA approved a supplemental BLA for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited. The action concerns regulatory approval rel…
-
FDA approval · 2025-09-03FDA Approved: INFLECTRA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Inflectra (infliximab-dyyb) from Pfizer to update its labeling and/or indications, following…
-
EMA approval · 2025-08-27EMA Authorised: Kyntheum (brodalumab) — LEO Pharma A/S
EMA authorised Kyntheum (brodalumab) by LEO Pharma A/S for psoriasis; decision date 27 August 2025.
-
FDA approval · 2025-08-14FDA Approved: OTULFI — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for OTULFI (ustekinumab-AAUZ) from Fresenius Kabi USA, LLC.
-
FDA approval · 2025-07-29FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Sandoz Inc for the adalimumab biosimilar ADALIMUMAB-ADAZ, enabling its use with indications cons…
-
FDA approval · 2025-07-18FDA Approved: FLUOCINOLONE ACETONIDE OIL — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Fluocinonide Acetonide Oil, a topical corticosteroid product from Rising Pharma Holdings, In…
-
FDA approval · 2025-05-22FDA Approved: STARJEMZA — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved STARJEMZA (ustekinumab-hmny) from Hikma Pharmaceuticals USA Inc. as a biosimilar to ustekinumab, enabling marketing for the sam…
-
FDA approval · 2025-04-30FDA Approved: USTEKINUMAB-TTWE — Original Application (Quallent Pharmaceuticals Health LLC)
FDA approves an original biologics license application for USTEKINUMAB-TTWE from Quallent Pharmaceuticals Health LLC.